GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » Enterprise Value

BLFS (BioLife Solutions) Enterprise Value : $986.14 Mil (As of Jun. 16, 2025)


View and export this data going back to 1989. Start your Free Trial

What is BioLife Solutions Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioLife Solutions's Enterprise Value is $986.14 Mil. BioLife Solutions's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-4.42 Mil. Therefore, BioLife Solutions's EV-to-EBIT ratio for today is -222.91.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, BioLife Solutions's Enterprise Value is $986.14 Mil. BioLife Solutions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $3.34 Mil. Therefore, BioLife Solutions's EV-to-EBITDA ratio for today is 294.99.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, BioLife Solutions's Enterprise Value is $986.14 Mil. BioLife Solutions's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $79.42 Mil. Therefore, BioLife Solutions's EV-to-Revenue ratio for today is 12.42.

EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, BioLife Solutions's Enterprise Value is $986.14 Mil. BioLife Solutions's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $11.29 Mil. Therefore, BioLife Solutions's EV-to-FCF ratio for today is 87.37.


BioLife Solutions Enterprise Value Historical Data

The historical data trend for BioLife Solutions's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Enterprise Value Chart

BioLife Solutions Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,238.68 1,515.58 760.55 723.61 1,143.30

BioLife Solutions Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 843.24 989.85 1,162.63 1,143.30 1,024.36

Competitive Comparison of BioLife Solutions's Enterprise Value

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions's Enterprise Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Enterprise Value distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Enterprise Value falls into.


;
;

BioLife Solutions Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

BioLife Solutions's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as

BioLife Solutions's Enterprise Value for the quarter that ended in Mar. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLife Solutions  (NAS:BLFS) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

BioLife Solutions's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=986.141/-4.424
=-222.91

BioLife Solutions's current Enterprise Value is $986.14 Mil.
BioLife Solutions's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.42 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

BioLife Solutions's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=986.141/3.343
=294.99

BioLife Solutions's current Enterprise Value is $986.14 Mil.
BioLife Solutions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.34 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

BioLife Solutions's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=986.141/79.416
=12.42

BioLife Solutions's current Enterprise Value is $986.14 Mil.
BioLife Solutions's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $79.42 Mil.

4. EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow.

BioLife Solutions's EV-to-FCF for today is:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=986.141/11.287
=87.37

BioLife Solutions's current Enterprise Value is $986.14 Mil.
BioLife Solutions's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLife Solutions Enterprise Value Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLife Solutions Business Description

Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Executives
Sarah Aebersold officer: VP, Global Human Resources BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman officer: Chief Financial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Aby J. Mathew officer: Chief Tech. Officer & Sr. VP 3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard officer: Vice President, Marketing 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster officer: Vice President of Operations C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Amy Duross director 8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Greef Roderick De director
Garrie Richardson officer: Chief Revenue Officer 3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Geraint Phillips officer: SVP, Global Operations 3303 MONTE VILLA, #310, BOTHELL WA 98021
Michael Rice director, officer: President & CEO C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Marcus Schulz officer: Vice President, Global Sales 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick director 16719 NE 139TH PLACE, WOODINVILLE WA 98072
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami director SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023